Rheumatology Journals

Rheumatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Farge D et al. – This largest cohort studied worldwide shows that autologous HSCT can induce sustained remissions for more than 5 years in patients with severe AD refractory to conventional therapy. AD disease type, rather than transplant techniques, was the most relevant determinant of outcome. Results improved with time and were associated with centre experience. The data support ongoing and planned phase III trials to evaluate the place of autologous HSCT in the treatment strategy for severe AD.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address